Filing Details
- Accession Number:
- 0001104659-25-074399
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-08-05 20:30:11
- Reporting Period:
- 2025-08-01
- Filing Date:
- 2025-08-05
- Accepted Time:
- 2025-08-05 20:30:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1657312 | Verona Pharma Plc | VRNA | () |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2014301 | Andrew Fisher | 3 More London Riverside London X0 SE1 2RE | General Counsel | No | Yes | No | No |
Transaction Summary
| Sold: | 9,584 shares | Avg. Price: $13.14 | Total Value: $125,969.22 |
| Number of Shares After Transactions: | 417,903 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-08-01 | 20,888 | $0.00 | 427,487 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2025-08-01 | 9,584 | $13.14 | 417,903 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Stock Units | Disposition | 2025-08-01 | 20,888 | $0.00 | 20,888 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 146,168 | No | 4 | M | Direct |
Footnotes
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs").
- The price reported represents the sale price of the ADSs divided by eight (8).
- Consists of (i) 300,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 37,500 ADSs), (ii) 117,896 Ordinary Shares underlying 14,737 ADSs, and (iii) 7 Ordinary Shares.
- Represents an award of performance-based RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
- The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q1 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of August 1, November 1, February 1 and May 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Billionaire Hedge Funds
